Drug Reviews Would Grind To A Halt Without PBPK Software, US FDA Asserts
Executive Summary
Notice to renew reviewers’ access to Certara’s Simcyp software quickly via single source procurement outlines how critically dependent the FDA, like many other organizations, is on tech tools.
You may also be interested in...
FDA Endorses PBPK Modeling To Support Post-Approval Changes
The US FDA endorses the use of physiologically based pharmacokinetic (PBPK) models to support formulation and manufacturing changes.
Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention
Foreign tablets, active pharmaceutical ingredient residues and failed line clearance plagued operations at repackers that received FDA warning letters in FY 2023.
US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage
Director of the FDA’s center for drugs slams firm for failing to reach out before suspending operations in the wake of an inspection that raised serious data integrity concerns. Instead, firms should be alerting the agency as soon as they realize there could be shortages.